Gretchen Gignac, MD
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology Section

MD, University of Pennsylvania School of Medicine



Expertise in genitourinary clinical research.

Active Staff Privileges
Boston Medical Center
Department of Medicine




A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orternel (TAK-700) Plus Prednisone
06/01/2011 - 11/16/2015 (PI)
Millennium Pharmaceuticals, Inc.

A Randomized phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen to Cabazitaxel/Prednisone for second line chemotherapy in men with metastatic castrte resistant prostate cance
09/28/2012 - 08/13/2015 (PI)
OncoGenex Technologies, Inc

A phase 3, Randomized, Double-blind, controlled study of cabozantinib (XL184) vs. Prednisone in Metastatic castration resistant prostate cancer patients who have received prior cocetaxel and prior abi
10/19/2012 - 10/19/2014 (PI)
Exelixis, Inc

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednisone in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
06/01/2011 - 05/31/2014 (PI)
Millennium Pharmaceuticals, Inc.

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orternel (TAK-700) Plus Prednisone
06/01/2011 - 05/31/2014 (PI)
Millennium Pharmaceuticals, Inc.




Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Karantanos T, Karanika S, Gignac G. Uncontrolled diabetes predicts poor response to novel antiandrogens. Endocr Relat Cancer. 2016 Sep; 23(9):691-8. PMID: 27515296; DOI: 10.1530/ERC-16-0222;.
  2. Gunnarsson O, Basaria S, Gignac GA. Cardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy. Cancers (Basel). 2015; 7(2):679-87. PMID: 25913100; DOI: 10.3390/cancers7020679;.
  3. Gunnarsson O, Basaria S, Gignac G. The prevalence of metabolic risk factors in black men with prostate cancer undergoing consideration for androgen-deprivation therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):e15082. PMID: 28020432.
  4. Hirsch AE, Cuaron JJ, Janicek MJ, Mui K, Lee RJ, Wang DS, Babayan RK, Zumwalt AC, Gignac GA, Tao W, Ozonoff A, Zietman AL. Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Pract Radiat Oncol. 2011 Apr-Jun; 1(2):115-25.View Related Profiles. PMID: 24673925; DOI: 10.1016/j.prro.2010.11.007;.
  5. Ariel E. Hirsch, John J. Cuaron, Milos J. Janicek, Kit Mui, Richard J. Lee, David S. Wang, Richard K. Babayan, Ann C. Zumwalt, Gretchen A. Gignac, Wen Tao, Alexander Ozonoff, Anthony L. Zietman et al. . Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Practical Radiation Oncology. 2011; 1(2):115-125.
  6. Chi D, Hirsch AE, Gignac GA. Biochemical failure after radiation therapy for prostate cancer: Racial differences. J Clin Oncol. 2009 May 20; 27(15_suppl):e16071.View Related Profiles. PMID: 27963037.
  7. Dickstein RJ, Kreshover JE, Milose JC, Gignac GA. Metastatic prostate cancer at diagnosis: Clinical presentation in the post-PSA era. J Clin Oncol. 2009 May 20; 27(15_suppl):e16159. PMID: 27963401.
  8. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 May 20; 27(15):2436-42. PMID: 19364960; PMCID: PMC2684850; DOI: 10.1200/JCO.2008.20.4164;.
  9. Gignac GA, Morris MJ, Heller G, Schwartz LH, Scher HI. Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer. 2008 Sep 1; 113(5):966-74. PMID: 18661513; PMCID: PMC2708077; DOI: 10.1002/cncr.23719;.
  10. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007 Dec 1; 13(23):7053-8. PMID: 18056182.
Showing 10 of 13 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 13 publications over 8 distinct years, with a maximum of 3 publications in 2009 and 2011

YearPublications
20021
20061
20072
20081
20093
20113
20151
20161

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Project Mentor
Contact for Mentoring:


820 Harrison Ave
Boston MA 02118
Google Map


Gignac's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department